RecruitingPhase 3NCT07576959

Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication

Effect of Bismuth Add-on to Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Eradication - A Multicenter Randomized Controlled Trial

Sponsor

National Taiwan University Hospital

Enrollment

990 participants

Start Date

Apr 8, 2026

Study Type

INTERVENTIONAL

Conditions

Helicobacter Pylori Infections

Summary

This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bismuth Add-on to Vonoprazan Dual Therapy and a drug called Vonoprazan dual therapy for people with helicobacter pylori infections. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBismuth Add-on to Vonoprazan Dual Therapy

bismuth, vonoprazan and amoxicillin for 14 days

DRUGVonoprazan dual therapy

vonoprazan and amoxicillin for 14 days

Locations(1)

National Taiwan University Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07576959

Related Trials

Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection

NCT07275827

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

NCT072939101 location

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

NCT071791592 locations

Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.

NCT073069881 location

Registry for the Management of Helicobacter Pylori Infection in Shandong Province

NCT073354062 locations